Precision BioSciences (NASDAQ:DTIL) Stock: Insider Geno Germano Buys 2,609 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno Germano purchased 2,609 shares of the firm’s stock in a transaction on Friday, September 25th. The stock was acquired at an average cost of $6.28 per share, for a total transaction of $16,384.52. Following the completion of the purchase, the director owned 47,492 shares in the company, valued at $298,249.76. The trade was a 5.81% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Precision BioSciences Stock Up 0.3%

DTIL opened at $6.24 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 12.82 and a quick ratio of 12.82. The stock has a market capitalization of $172.22 million, a price-to-earnings ratio of -2.23 and a beta of 1.24. The business has a 50-day moving average of $7.37 and a two-hundred day moving average of $7.19. Precision BioSciences, Inc. has a 12 month low of $3.53 and a 12 month high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. On average, research analysts expect that Precision BioSciences, Inc. will post -3.33 earnings per share for the current year.

Institutional Investors Weigh In On Precision BioSciences

Large investors have recently made changes to their positions in the business. Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences during the 2nd quarter valued at $164,000. Squarepoint Ops LLC boosted its position in Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock worth $1,078,000 after purchasing an additional 93,258 shares during the period. Corient Private Wealth LP increased its holdings in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after purchasing an additional 101,206 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Precision BioSciences in the 2nd quarter valued at $467,000. Finally, Bank of America Corp DE raised its position in Precision BioSciences by 167.6% in the first quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after purchasing an additional 17,172 shares during the period. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on DTIL shares. Oppenheimer assumed coverage on Precision BioSciences in a report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price objective for the company. Wall Street Zen cut Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.25.

About Precision BioSciences